| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  Igyxos Igyxos develop more effective/efficient infertility treatment for patients Igyxos is a biotechnology company based out of CENTRE INRAe VAL DE LOIRE SITE DE TOURS, NOUZILLY, France. Biotechnologie, Fertilité, and anticorps monoclonal 194 similar entities Type: SMB Activities: biotech healthtech Technologies: Synthetic Biology | 2 | 14 |
 |  StemTek Therapeutics StemTek Therapeutics is a start-up biotechnolgy company dedicated to accelerating drug discovery in cancer using cutting edge technology, world-class science and a stem cell centric point of view for cancer therapy. Our mission is to help design novel treatments for cancer targeting cancer stem cells. 133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 1 |
 | Astellas Gene Therapies Follow Astellas Pharma for updates on our pipeline of genetic medicines for patients with rare diseases. The Astellas Gene Therapies page is no longer active or monitored. gene therapy and biotechnology 59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 406 |
 | Olgram marine-inspired molecules to fight immunological diseases Olgram is a biotechnology company developing first-in-class, proprietary immunotherapies to treat immune deficiencies, beginning with immuno-depression after traumatic brain injury and concussion. Biotechnologie, immunologie, antibiorésistance, and commotions 69 similar entities Type: Startup Activities: deeptech biotech | 5 | 5 |
 | BforCure Advanced molecular analysis technologies to harness the power of the microbiota. To be more responsive, more efficient and make better decisions, BforCure allows public and industrial stakeholders to access biological information in real time, thanks to an innovative technology of rapid biodetection. 68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 28 |
 | Evexta Bio Evexta Bio, formerly #Diaccurate, is a biopharmaceutical company exploring the new frontiers of #oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications: - Rupitasertib, formerly DIACC3010, an optimized S6K inhibitor with efficient AKT1/AKT3 control of feed-back loop. The oral anti-tumor agent is expected to enter phase 2/3 clinical trial in refractory ER+ HER2- metastatic breast cancer. - EVX020, formerly DIACC2020, an antibody-drug conjugate program using a sole-in-class KIF20A kinesin inhibitor as payload in … 75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 10 |
 | Cocoon Bioscience Proteins For Sustainability Cocoon Bioscience specializes in the manufacturing of high performance growth factors and enzymes using an automated platform leveraging cocooned insects as natural, low cost bioreactors. 173 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology | 3 | 41 |
 | Icosagen European Mammalian CRDMO - From Discovery mgs to Clinical GMP kgs. We're a leading European biotechnology company, providing streamlined or custom-tailored services for global clients in pharmaceutical, biotechnology industries, and academia. We've been a privately held family business since 1999, and have grown into a leading mammalian Contract Research, Development, and Manufacturing Organization (CRDMO). The CRDMO approach allows us to cover the entire spectrum of pre-clinical and clinical services - from the initial stages of target discovery and development, to cell line development, and manufacturing of mammalian therapeutic proteins, up to 1000 L scale. In 2023, we worked with more … 136 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 148 |
 | Aida Oncology Helping cancer patients to get the right drugs Cancer is a disease with millions of variations where even the most effective current treatment protocols will not work for many patients. We at AIDA believe that modern high-performance computing and machine learning combined with cutting-edge gene reading tools can fast forward personalized cancer therapy and improve treatment options for cancer patients. 37 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning | 0 | 10 |
 | MPC Therapeutics Biotech company focused on cellular rejuvenation to fight cancer & degenerative pathologies. At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info. Longevity, Mitochondria, Cellular rejuvenation, Immunotherapy, and CAR T cell therapy 37 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 7 |
 |  Inventiva Pharma A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc 154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 124 |
 | GLYcoDiag Glycoscience and microbiota research specialized company GLYcoDiag is a French research company (SME) specialized in glycosciences and microbiote services and product. Our business area covers the domains of human and animal health (biomarkers, therapeutic recombinant glycoproteins, vaccines), cosmetics (active ingredients, design and mechanisms of “glyco-actives”) and environment (biofilms, waste water). glycobiology, lectins glycoprofiling, oligosaccharides, glycoconjugates, microbiota, glycosciences, and cosmetics 65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 3 |
 | Devicare The Digital Therapeutic Company in Urology Devicare is a specialty biotech company dedicated to develop pathbreaking medical treatments in Urology combining the most recent scientific advances in nutritional therapy with digital technologies. Biotechnology, Medical devices , Digital Health , eHealth, Healthcare, and Digital Therapeutics 383 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 7 | 31 |
 | Peptone Drugging disordered proteins with physics and AI Peptone is a therapeutics company that uses AI and an experimental physics product engine to design small molecules targeting the 6,200 intrinsically disordered human proteins that Alpha Fold 3 cannot model. artificial intelligence, structural biology, high performance computing, supercomputers, biotechnology, and intrinsically disordered proteins 142 similar entities Type: Startup Activities: biotech deeptech it services Technologies: Synthetic Biology | 46 | 43 |
 | CureMatch, Inc. AI-based Precision Medicine Decision Support for Oncology CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient’s tumor. digital health, oncology, decision support software, AI, precision medicine, and combination therapy 78 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: A.I. Synthetic Biology | 5 | 26 |
 | Ikena Oncology Patient-directed oncology therapies across pathways relevant in tumor and immune cells Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which … 126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 23 |
 | Aridis Pharmaceuticals Leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections Aridis Pharmaceuticals is a late-stage clinical development company leading the creation of transformative, first-in-class anti-infectives for life-threatening respiratory infections. The company’s pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of antimicrobial resistant bacteria (AMR). Monoclonal Antibody , Infectious Disease, Cell line Engineering, Inhalation therapy 106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 23 |
 | Selexis SA Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, … 142 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 27 |
 | Symphogen Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL 155 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 194 |
 | BioCryst Pharmaceuticals, Inc. We develop oral small-molecule and protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. We are a commercial-stage biotech company with US headquarters in Durham, North Carolina. Our European headquarters is in Dublin, Ireland, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices … 151 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 635 |
 | GTP Bioways - Olon Company Customer-centric and science-driven CDMO supporting biopharma companies from R&D to market GTP Bioways is an expert and fast-growing contract development and manufacturing organisation (CDMO) offering uniquely customised process development and manufacturing services for biologics, antibody-drug conjugates and nanodrugs. With cutting-edge facilities located in France, GTP Bioways supports biopharma companies in bringing their innovative molecules from research to clinic and market. GTP Bioways is an Olon company. Biologics, Nanodrugs, Process Development, Analytics, Biopharmaceuticals, and GMP Manufacturing 61 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 24 | 157 |
 | MiNA Therapeutics Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery 213 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 33 |
 | QuantuMDx Transforming Point of Need Multiplex Diagnostics QuantuMDx is a progressive MedTech company passionate about creating multiplex molecular diagnostic solutions for use at the point of need. MedTech, Molecular Diagnostics, Multiplex Molecular Diagnostics, Point of Care, Point of Need, COVID-19, Medical device, Diagnostic device, DNA extraction, TB, Sepsis, Transcriptomics, PCR, Microarray, Assay Development, Assay Feasibility, Rapid Diagnostics, Respiratory Infections, Sexually Transmitted Infections, Host Response, and In vitro Diagnostics 154 similar entities Type: Startup Activities: deeptech biotech healthtech nanotech Technologies: Synthetic Biology | 8 | 86 |
 | Cellomatics Biosciences Ltd Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory 376 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 19 |
 | Instituto de Biología Molecular y Celular de Plantas, IBMCP (UPV - CSIC) Discovering from Green - Scientific research aimed at obtaining plants with better productivity, fruit quality or with high -value added properties (of interest to the consumer, farmers and the agri -food industry) and more stress resistant, as well as less dependent on chemical treatments, in order to contribute to less aggressive agriculture with the environment. - Advanced genomics, proteomic, metabolomic, bioinformatics, microscopy, quantification of plant hormones, DNA sequencing and gene expression analysis. - Training of research personnel. Biotechnology, Molecular Biology, Genomic, Proteomic, Bioinformatics, Metabolomics, Systems Biology, and Synthetic Biology 251 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 3 | 201 |
 | AGV Discovery AGV Discovery offers services in chemistry, cell biology, in vitro screening, rational drug design, outsourcing and consultancy. AGV Discovery is a pharmaceutics that specializes in rational design and early development of drug candidates. 61 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology | 0 | 7 |
 | Cherry Biotech Alternative to Animal Testing for Drug Development Cherry Biotech is a biomedical technology (Organ on Chip) company that develops instruments for drug discovery and personalised medicine. Its mission is to replace animal testing by reconstructing human tissue (Organoids) in vitro for drug testing. Cherry Biotech's CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates. By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech's proprietary CUBIX technology is the only solution that can convert … 56 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 9 | 24 |
 | TISSIUM Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully … 83 similar entities Tags: FrenchTech120 Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 18 | 132 |
 | CENTOGENE Empowering precision medicine through advanced diagnosis CENTOGENE is a leading company in the field of genetic diagnostics and precision medicine, dedicated to transforming clinical, genetic, and biochemical data into medical solutions for patients. Based in Rostock, Germany, the company operates globally. Founded in 2006 with the mission of revolutionizing the diagnosis of rare diseases, CENTOGENE has since scaled its capabilities to diagnose more than 2,500 rare diseases in over 100 countries, building one of the largest genetic databases in the world (1,000,000 individuals) while developing cutting-edge technology for the interpretation of genetic data. With over 350 scientific publications, CENTOGENE is … 155 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 25 | 404 |
 | Causeway Sensors Limited Causeway Sensors uses nanotechnology to provide better candidate selection during drug development. The company spun-out after years of high-impact research at Queen's University Belfast. Our unique nanochip platform brings real-time, label-free kinetic analysis to areas of biotherapeutic production where such data cannot currently be collected. More data at critical points of production helps pharma companies ensure that only the best drug candidates progress to clinical trials. The platform can be incorporated into a multitude of form factors, ranging from a high-throughput screening instrument to an in-line cell culture monitoring tool. Biosensing, Protein - Protein Interactions, Binding Kinetics, Biotechnology, Biotherapeutics, Antibody … 91 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 3 | 12 |
 | Dragonfly Therapeutics, Inc. Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel multispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly owned clinical assets, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas. For more information, email info@dragonflytx.com. immuno-oncology 66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 109 |
 | Skyhawk Therapeutics We Use Small Molecules To Modify RNA Splicing Skyhawk Therapeutics is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that modify RNA expression. Our founders are leading experts in small molecule therapeutics development for RNA-based disease. Our first drug candidates are targeted toward cancers and neurological conditions. The company is based in Waltham, Massachusetts. For more information, please visit: www.skyhawktx.com. 73 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 69 |
 | Poseida Therapeutics, Inc. A Member of the Roche Group Poseida was acquired by Roche in early 2025 and is now part of the Roche Group. Poseida is a clinical-stage biopharmaceutical company advancing differentiated allogeneic cell therapies and genetic medicines with the capacity to cure. The Company's approach is based on its proprietary genetic editing platforms, including its non-viral DNA Delivery System, Cas-CLOVERTM Site-Specific Gene Editing System, Booster Molecule and nanoparticle gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Genome Engineering, CAR-T cells, Gene Therapy, Gene Editing, Cell Therapy, Adoptive Cell Therapy, Multiple Myeloma, Prostate Cancer, Transposon, Non-viral, Biotechnology, Immunotherapy, Regenerative … 77 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 334 |
 | Abzena Abzena is the leading end-to-end bioconjugate & complex biologics CDMO+CRO, focused on rapidly moving medicines forward. Abzena is the leading end-to-end bioconjugate, ADC, and complex biologics CDMO + CRO. From discovery through commercial launch, we support customers with fully integrated programs or individual services designed to de-risk and streamline the development of new treatments for patients in need. With the ability to tailor its strategy and customer experience to each project, Abzena develops and implements innovative solutions that enable biotech and biopharma companies to realize the full potential of their molecule and move medicines forward faster. The company has research, … 75 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology | 7 | 434 |
 | Precigen Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies. Precigen: Advancing Medicine with PrecisionTM Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and … 63 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 130 |
 |  coIMMUNE, Inc. coIMMUNE is a privately held, clinical stage immune-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a novel CAR therapy that promises enhanced efficacy with greatly reduced toxicity. 108 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 5 | 8 |
 | InCarda Therapeutics Pioneering inhaled medications for cardiovascular conditions InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The lead product under development is an inhaled therapy to treat a common atrial arrhythmia, paroxysmal atrial fibrillation (PAF). Cardiovascular, Inhalation therapy, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Commercialization, Clinical Research, Pre-Clinical Research, and Regulatory Affairs 88 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 14 |
 | MindMed MindMed is a clinical-stage biopharma company developing novel products to treat brain health disorders MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the … 55 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 6 | 108 |
 | Nagi Bioscience in vivo testing at the in vitro scale At Nagi Bioscience, we develop cutting-edge biological testing solutions enabling scientists to generate the insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our pioneering Organism-on-Chip platform, SydLabTM One, seamlessly integrates into existing lab environments, enabling scientists to enhance efficiency, accuracy, and reproducibility like never before. By combining this innovative technology with our team’s expertise, we deliver customer-focused solutions that empower scientists to advance research and drive scientific thinking forward. #inwormwetrust Microfluidic technology, Drug Screening, Pre-clinical studies, Lab Automation Technology, Safety and Efficacy, Toxicology, AI, C. … 184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 47 |
 | Sonata Therapeutics Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences … 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 23 |
 | Bioxis Pharmaceuticals #BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid 301 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology | 5 | 29 |
 | Insight Biosolutions Your safety passport for cosmetic ingredients & drug candidates Your partner for toxicological risk assessment requests Using our digital solutions increases the product safety and reduces the product development cost up by 30%. Insight Biosolutions (IBS) with his expert network has developed specialized platforms for in vitro and in silico services. IBS develops digital tools and services for the cosmetics and pharmaceutical industries. Computational Toxicology, in vitro toxicology , Safety assessment, Drug Discovery, Molecular Modeling, Computational Chemistry, CPSR, Pre Clinical screening, ADME, and PBPK 83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 4 |
 | InVenis Biotherapies Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis. 217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 7 | 2 |
 | Coral Biome PHARMA CORAL BIOME PHARMA Live cultured corals for Drug discovery Coral Biome is a research and development company dedicated to the discovery of marine natural products of interest for major public health issues such as cancer, inflammation and multi-drug resistant infectious diseases. Our multidisciplinary team of research and worldwide network of collaborators gathers a unique set of competitive expertise including, aquaculture, marine biology, chemistry, cell biology and cancerology to successfully isolate marine natural products and test their biological activity. We maintain a large-scale untapped reservoir of coral species to preserve endangered species, sell corals for aquarium trade (http://www.coralbiome.com/aquaculture/) and provide research … 26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 1 |
 | PepKon PepKon is a french biotechnology company founded in 2022. The company develops first-in-class peptides for the treatment of incurable or poor prognosis cancers. These drug-candidates come from over a decade of academic research, resulting in seven scientific publications and two patent families 134 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 8 |
 | UNIVERCELLS For humanity to thrive, we need transformative thinking in how vaccines and therapeutics are designed and produced. At Univercells, we believe in the power of small adaptations to drive big change. We embrace the spirit of evolution in everything we do. We are biotech innovators. We are scientists and entrepreneurs creating transformative platforms for the pharmaceutical and biotech industry, through technology, bioprocess know-how and entrepreneurial spirit. Biotechnology, mRNA, CDMO, and Services 88 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology | 4 | 90 |
 | ReCode Therapeutics Powering the next wave of genetic medicines through superior delivery ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. RNA Therapies, Genetic Medicines, Non-Viral Lipid Nanoparticles, Genetic Respiratory Disease, Cystic Fibrosis, Primary Ciliary Dyskinesia, and Biotechnology 88 similar entities Type: Startup Activities: deeptech biotech nanotech Technologies: Synthetic Biology | 4 | 108 |
 | Made Scientific Defy Limits. Deliver Results. Made Scientific is a leading cell therapy contract development and manufacturing organization (CDMO) dedicated to advancing the field of cell therapy. Since 2019, the company has specialized in developing, manufacturing, and releasing autologous and allogeneic cell therapy products for early- to mid-stage clinical trials, and has evolved into an end-to-end clinical-to-commercial service provider. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the flexibility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. CDMO, Process Development, Analytical … 88 similar entities Type: Startup Activities: manufacturing biotech deeptech Technologies: Synthetic Biology | 3 | 73 |
 | Century Therapeutics, Inc Harnessing the power of adult stem cells to develop curative therapies for cancer and autoimmune diseases Our genetically engineered, iPSC-derived cell products are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of … 100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 178 |
 | OxSonics Therapeutics Tackling the toughest cancers. We’re OxSonics, a pioneering clinical-stage therapeutics company committed to developing a ground-breaking platform technology to make anti-cancer drugs smarter, act faster and, above all, work better. Our SonoTran® Platform has been designed to actively enhance the delivery of oncology drugs into solid tumours. SonoTran® is drug agnostic and requires no drug reformulation enabling its use with both existing and novel therapies. We have our own development programs as well as collaborations with Pharmaceutical and biotech companies to work to bring smarter, faster and better therapies to as many patient groups as possible. Drug Delivery, Oncology, Medical … 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 15 |
 | TriSalus Life Sciences TriSalus Life Sciences® seeks to transform outcomes for patients with solid tumors TriSalus Life Sciences is an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. 138 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 108 |
 | OMass Therapeutics OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital. 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 14 | 87 |
 | AOA Dx Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GDTM, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer. Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, … 57 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 7 | 54 |
 | Artus Therapeutics Sealing The Broken Barrier Currently we are not hiring. Please beware of scammers Artus is a pre-clinical stage company developing first-in-class therapeutics for inflammatory and metabolic diseases by targeting barrier dysfunction. 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 3 |
 | Alvotech Better Access. Better Lives. Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars. Biopharmaceuticals, Research and Development, Biosimilars, Biotechnology, Pharmaceutical, Biogenerics, Health, Cell Line Development, Business Development, and Regulatory 232 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 942 |
 | Generare Natural molecule discovery, industrialized Natural products have contributed more than 500 molecules to pharmaceuticals. However, conventional methods for discovering new natural products are increasingly ineffective. Generare has developed a revolutionary platform that identifies and expresses a wide range of naturally occurring secondary metabolites, selected by millions of years of bacterial evolution. This platform allows us to reintroduce these lead molecules into clinical pipelines, reopening a validated avenue for therapeutic innovation. genomics, synbio, and microbiology 100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 8 | 21 |
 | Zionexa Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers 62 similar entities Type: Startup Activities: biotech deeptech | 0 | 6 |
 | PulseSight Therapeutics PulseSight is an ophthalmology drug development company developing disruptive non-viral gene therapies with minimally-invasive delivery technology to treat major eye diseases. Our mission is to develop life-changing solutions for patients with diseases leading to sight loss. 83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 9 |
 | Feeligreen Dermo-innovation Feeligreen is a technology startup developing safe and effective micro-current devices for a wide range of cosmetic and therapeutic applications. With applications ranging from anti-ageing to wound healing, it develops and sells innovative drug-delivery systems to TIer1 pharmaceutical laboratories medical devices, therapeutics, cosmetics, and skincare 134 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology | 12 | 3 |
 | CYNBIOSE Exploring together! We support biopharmaceutical research with translational preclinical models. CYNBIOSE is France-based non-clinical research organization. Preclinical CRO, Pharmacokinetics, POC, Efficacy, Immunotherapies, Drug, Early tox, CNS, Infectious diseases, Respiratory diseases, Non clinical, CRO, PK, PD, and TK 69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 19 |
 | Farmabios, member of Axplora We supply the world with active pharmaceutical ingredients Farmabios is a leading global manufacturer of highly potent active pharmaceutical ingredients. With decades of steroid and complex chemistry expertise, and newly opened research and development projects in various fields, Farmabios provides bespoke products and solutions, understanding customer needs. Steroids, Chemistry, Active Pharmaceutical Ingredients, Hormones, Drug Substances, Healthcare, Pharmaceuticals, and Bespoke products 62 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 129 |
 | NMR - Bio From Molecules to Medicine and Beyond NMR-Bio is a CRO located in Grenoble (France), one of the most vibrant European hubs for structural biology and supplies compounds for the selective labelling of methyl groups in perdeuterated proteins. NMR-Bio also offers a broad range of services for NMR applications: - Custom labelled protein production in bacteria, cell-free system, insect cells, HEK293 and CHO cells - Solution for labelling of your biopharmaceutics especially mAbs and Fabs - High-field NMR data acquisition and analysis (e.g. quality control, spectra assignment, structure calculation, dynamic characterisation). 59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 3 |
 | ELSALYS BIOTECH Innovative medicines to address haemato-oncology related life-threatening and rare diseases ElsaLys Biotech is a specialty pharmaceutical company, part of the Mediolanum Farmaceutici Spa group, focused on innovative medicines to address haemato-oncology related life-threatening and rare diseases. Following strategic acquisitions and targeted developments, ElsaLys is establishing an immunotherapeutic portfolio focused on niche specialty pharmaceuticals to answer unmet medical needs. Our commitment is to offer essential drugs meeting Public Health needs. Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole, in Lyon, France. Anticorps thérapeutiques, Anticorps monoclonaux, Therapeutic antibodies, Monoclonal antibodies, ophtalmologie, immune microenvironment, vascular … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 1 |
 | Genbiotech Bringing People & Ressources Together The creation of Genbiotech, a spinoff of the Laboratoires Genévrier results of 15 years of strategic involvement in biotechnological research with one goal: to improve the quality of life of patients in the field of rheumatology, dermatology and aesthetic. We believe that tomorrow medicine needs to be dedicated and targeted to patients. We aim to improve existing treatments by using non invasive processes allowing local and sustained administration of biological and active molécules. The company, incepted in 1998, has currently a staff of 11 people and is located in Sophia Antipolis (South of France). For … 58 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 8 |
 | ManRos Therapeutics From Sea to Pharmacy ManRos Therapeutics is a biotech company identifying, optimizing and characterizing innovative, low molecular weight kinase inhibitors for the treatment of cystic fibrosis. ManRos was founded in 2007 and is led by Dr Laurent MEIJER, Chairman and CSO, former distinguished Director of Research at the CNRS, and Dr Philippe de Lavenne, CEO, former Vice-President at Actelion Pharmaceuticals. For 40 years, Dr Meijer dedicated his research to the study of protein kinases and their inhibitors, mostly at the CNRS. Drug Development, Cystic Fibrosis, and Biotechnology 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 5 |
 | Ecrins Therapeutics Ecrins Therapeutics is a biotechnology company which focuses on the discovery and development of novel anti-cancer compounds from the preclinical phase to phase II clinical proof of concept. In addition to the drug discovery, Ecrins Therapeutics provides a range of products and services for the benefit of our customers in biotechnology companies, universities, public research institutions and in the pharmaceutical industry. The mission of the commercial division of Ecrins Therapeutics is to help medical chemists and drug hunters to discover, characterize and advance their lead compounds through the drug development process. Visit http://ecrins-therapeutics-services.com/ for more information. Our research and production … 47 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 3 | 1 |
 | Mablink Bioscience Transforming cancer immunotherapy with next generation ADCs Mablink Bioscience is a French biotechnology company that is actively involved in the fight against cancer by bringing disruptive therapeutic solutions. With its Antibody-Drug Conjugates (ADC) masking technology, Mablink Bioscience aims to dramatically improve the efficiency of ADC therapies and accelerate the development of new treatments. Based in Lyon, where it is developing an unprecedented innovation center, Mablink currently has around 30 employees with diverse backgrounds. biotechnology, drug development, drug discovery, oncology, and R&D 70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 15 | 35 |
 | ExAdEx-Innov Shaping the future of in vitro preclinical research Unique R&D platform of donor-derived real human adipose tissue ex vivo for pharmaceutical drug development (obesity, chronic metabolic diseases), dermo-cosmetic, nutraceutical, aesthetic and reconstructive surgery research. ExAdEx-Innov owns exclusive worldwide rights to ExAdEx patented breakthrough technology from French academic laboratories of excellence (Côte d’Azur University, Institut de Biologie Valrose, CNRS, INSERM, University Hospital of Nice) and is supported by SATT Sud-Est, IdEX Université Côte d'Azur, CNRS Innovation, Provence Côte d'Azur Business Incubator, Métropôle Nice Côte d’Azur and Eurobiomed Healthtech Accelerator. adipose tissue, cosmetic testing, research platform, in vitro, ex vivo, models, obesity, … 100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 22 | 6 |
 | Advesya Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune 398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 11 | 14 |
 | Biossan your partner for preclinical research Biossan : A French CRO dedicated to biomedical research Biossan helps its academic and industrial partners develop their innovations by performing preclinical trials under controlled conditions. Biossan specializes in evaluating medical devices, new techniques, and pharmaceutical products in healthy and pathological models. Conduite et accompagnement de projet de recherche, Organisation de formation, and Bien-être et expérimentation animale 89 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology | 1 | 1 |
 | Bionoveo Research center & amp; Health development Bionoveo offers project leaders, industrial or academic, biological, technical and methodological skills and resources necessary for the development of new therapeutic and diagnostic strategies, as well as their production processes. 283 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology | 5 | 4 |
 | BIONEEDS INDIA PRIVATE LIMITED BIONEEDS INDIA PRIVATE LIMITED is a Bangalore based Contract Research Organization providing Integrated Discovery, Development and Regulatory Services to Pharmaceutical, Biopharmaceutical, Agrochemical, Industrial chemical, Herbal/Nutraceutical and Medical device companies. Accreditation/Certifications • National GLP Compliance Monitoring Authority (NGCMA), Dept. of Science and Technology, Government of India • Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment, Forests and Climate Change, GOI. • State Drug Controller as a Government approved Drug Testing Laboratory for carrying out tests on Drugs / Cosmetics and • Raw Materials used in their manufacture on behalf of licensees for manufacture … 109 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 320 |
 | Genvade Therapeutics Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne 101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | N/A |
 | Nimbus Therapeutics We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 108 |
 | ElyssaMed SAS ElyssaMed® will develop the first therapeutic treatment for clinical use comprising several antigenic peptides (epitopes) derived from CTPP and selective for non-small-cell lung cancer, combined with an already marketed vaccine adjuvant. This product once administered to lung cancer patients, will amplify the patients' specific immune responses against tumor cells expressing the antigen CTPP and lead to their destruction. Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 2 |
 | AbTx Antibody for Therapy AbTx is a preclinical stage biotech company developing the next generation of oncology treatments to treat incurable cancers. AbTx platform is developing mAb innovative enzymatic conjugation. Our platform unlock New Frontiers in Medicine to overcome ADC major drawbacks associated targeting solid tumors by generating antibody Fragment Drug Conjugates (FDCs). ADC, Oncology, and drug develoment 70 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 7 | 4 |
 | Enodia Therapeutics Transforming treatment for cancer inflammation viral infection | Unveiling the Translocon to unlock innovative therapies Enodia Therapeutics, a French biotech company, is advancing first-in-class treatment for cancer, inflammatory diseases, and viral infections by targeting the translocon, a key gateway for protein secretion in the cell. Harnessing a cutting-edge AI-driven approach, we are developing selective small molecule inhibitors that block secretion and promote the degradation of pathological proteins at their source. Emerging from the Institut Pasteur and nurtured by Argobio, Enodia is built on breakthrough science with a singular mission: unveiling the translocon to unlock innovative therapies. Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | N/A |
 | INATHERYS Turning Cancer’s Energy Dependency Against Itself: a Shift in Precision Drug Delivery INATHERYS is a clinical-stage biotech advancing precision drug delivery, turning cancer’s energy dependency against itself. Our lead asset, an ADC targeting CD71/TfR1, is designed to address critical needs in treating proliferative cancers. 60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 9 | 4 |
 | MEDSENIC New therapeutic targets based on arsenic trioxide (As2O3) Founded in 2010, MEDSENIC is a biopharmaceutical start-up that aims to exploit the new possibilities offered by the therapeutic use of arsenic trioxide (As2O3) and thereby provide a treatment for patients with autoimmune diseases. santé, biotechnologies, bioparma, biopharmaceutical, biotech, health, biotechnology, autoimmune diseases, and maladies auto-immunes 346 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 4 |
 | Cell Environment Cyto-genomic technology to measure chromosomal health Cell Environment is a company created in 2016 that developed a new automated cyto-genomic approach combining new cytogenetics techniques with molecular genetics, based on 20 years of academic and private research. It allows to precisely analyse repetitive sequences (50% of the genome) as telomeres & centromeres and detect other chromosomal aberrations. This technology can be applied to better stratify populations for precision medicine in oncology for instance, to help diagnose some conditions as infertility or prenatal conditions, to measure toxic effects of certain treatments (in oncology) or of radiations, to measure the quality of … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 12 |
 | Nikaia Pharmaceuticals Unlocking the power of NIK to transform the future of cancer and autoimmune disease treatment Nikaia Pharmaceuticals, an innovative company dedicated to the discovery and development of cutting-edge therapeutic solutions to improve patients' lives. 🔬💊 Our mission is to push the boundaries of science to deliver novel and effective treatments, focusing on the NIK protein (NF-κB-inducing kinase) and developing molecules capable of blocking its action. 66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 4 |
 | TARIAN PHARMA Tarian Pharma's mission is to develop new drugs that ensure optimized cancer treatment by protecting cancer patients from side effects that would lead to dose reductions or discontinuation. This approach is designed to increase patients' chances of recovery and survival. Tarian Pharma was created by two dermatologists and a pharmacist, with more than 75 years of experience in the pharmaceutical industry and having been actively involved in the development and marketing of more than 15 new drugs in Europe, the United States and Asia. Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 2 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 235 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 20 |
 | Priothera SAS Adding Quality Years of Life We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) 207 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 15 | 20 |
 | VRG Therapeutics Regional leader in preclinical R&D with a world-class protein evolution tech platform for CGT applications Our mission is to cure diseases via targets and MoAs that cannot be reached with traditional approaches. Leveraging our unique platform, we optimize peptides/proteins of natural origin using directed evolution to create cutting-edge CGT products or peptide-based pharmaceuticals. VRGT’s management and staff members were selected based on their international research experience and outstanding pharma industry achievements. Our people have outstanding professional expertise in preclinical/clinical R&D and scientific project management, pharmacology, business development and medical marketing. For years, they have worked in the most prestigious academic … 158 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 27 |
 | Molecular Partners Pioneering DARPin Therapeutics for Patients Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA. DARPins, Oncology, Immuno-Oncology, Radiopharmaceuticals, … 82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 176 |
 | Physiogenex Leading preclinical CRO specializing in metabolic disorders. Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, ...) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions … 63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 24 |
 | Neopharm Boston CRO with extensive expertise in small molecule chromatography and purification We are Neopharm Boston Inc., formerly Averica Discovery Services, a Contract Research Organization (CRO) recognized by our proficiency in small molecule analysis and purification. Our enduring legacy of excellence positions us as a strategic partner within the pharmaceutical industry. Our recent expansion has equipped us to deliver a comprehensive, fully integrated array of services, facilitating a seamless journey from development and preclinical stage to commercial launch. At Neopharm Boston, our remarkable high throughput capabilities extend beyond advanced instrumentation to encompass a highly skilled and capable team. This synergy enables us … 62 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 3 | 160 |
 | Venatorx Pharmaceuticals, Inc. Discovering & developing novel anti-infectives to treat multi-drug resistant bacterial & hard-to-treat viral infections. Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. antibiotics, antiinfectives, antivirals, drug development, drug discovery, pharmaceuticals, #battlesuperbugs, #WorkingToFightAMR, clinical, research, #squashsuperbugs, biotech, and antimicrobialresistance 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 72 |
 | Quanterix Discovery Fueled by Ultra-Sensitivity Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research … 92 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 16 | 430 |
 | POLYVALAN Proteins Structures Got Easier With Crystallophores Emerged from academic research, POLYVALAN (IBS & ENS Lyon Spin-off company) is a young innovative company founded in December 2016 dedicated to structural biology. POLYVALAN competitive edge is its unique chemical approach allowing significant gain of effectiveness, time and/or precision for protein structure determination that allows an optimal use of the existing large equipments. structural biology, protein crystallization, crystallization screening, nucleating agent, phasing agent, crystallophore, structure determination, X-ray crystallography, and drug design 59 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 2 | 3 |
 | Orakl Oncology Biology x AI-powered drug development platform to transform precision oncology. Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster. 64 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 2 | 20 |
 | TheraPPI Bioscience Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease 80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 6 |
 | Blue Bees Therapeutics Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug 176 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 9 |
 | Deeptope Advanced Antibody Expertise Deeptope's expertise lies in antibody charaterisation (epitope/paratope mapping) and optimisation using high throughput methods. antibody, paratope mapping, epitope mapping, and antibody optimisation 77 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 7 |
 | Sirius NeoSight New view for cancer Therapeutic Sirius Neosight is an innovative technological breakdown company which aims to become a key player in the detection of subclashed neo-cancers, relapses and therapeutic monitoring of patients thus offering a new look to doctors on the therapeutic efficiency implemented. Sirius Neosight operates a patented from a patented rupture technology from a consortium of academic laboratory experts in the field. 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 19 | 8 |
 | Stimunity Turn cancer immunotherapies active in most patient Stimunity is a startup company from Institut Curie which develops bio-pharmaceuticals to treat patients that do not respond to immunotherapy in cancer. 25 similar entities Type: Startup Activities: biotech deeptech | 3 | 5 |
 | Asuragen, a Bio-Techne brand People Deserve Better Answers Asuragen, a Bio-Techne brand, is a molecular diagnostic product company changing the way patients are treated in genetics and oncology. Asuragen’s diagnostic systems, composed of proprietary chemistry and software, deliver powerful answers using broadly installed instrument platforms. They are simple to adopt and expand the ability to serve patients. Asuragen is a product foundry rapidly and efficiently addressing current and emerging clinical needs, including cancer diagnosis and monitoring, reproductive health and aging, serving laboratories across a patient’s lifespan with its best in class diagnostic tests. Bio-Techne a global life sciences company providing innovative tools and bioactive … 11 similar entities Type: SMB Activities: deeptech biotech Technologies: SaaS | 3 | 126 |
 | AbLeads AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine 574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 1 |
 | NanoMedSyn NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for … 156 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 4 |